Thus, hybridization of MLCs and HSA into a hyaluronic acid hydrogel could be a promising strategy for a sustained drug release system with biocompatibility and could be applied to the treatment of Alzheimer’s disease. Here, ALB is linked to early-onset autosomal dominant Alzheimer disease.